Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action

• Verfasst von: Escher, Sylvia E. [VerfasserIn]
• Verfasst von: Aguayo-Orozco, Alejandro [VerfasserIn]
• Verfasst von: Benfenati, Emilio [VerfasserIn]
• Verfasst von: Bitsch, Annette [VerfasserIn]
• Verfasst von: Braunbeck, Thomas [VerfasserIn]
• Verfasst von: Brotzmann, Katharina [VerfasserIn]
• Verfasst von: Bois, Frederic [VerfasserIn]
• Verfasst von: van der Burg, Bart [VerfasserIn]
• Verfasst von: Castel, Jose [VerfasserIn]
• Verfasst von: Exner, Thomas [VerfasserIn]
• Verfasst von: Gadaleta, Domenico [VerfasserIn]
• Verfasst von: Gardner, Iain [VerfasserIn]
• Verfasst von: Goldmann, Daria [VerfasserIn]
• Verfasst von: Hatley, Oliver [VerfasserIn]
• Verfasst von: Golbamaki, Nazanin [VerfasserIn]
• Verfasst von: Graepel, Rabea [VerfasserIn]
• Verfasst von: Jennings, Paul [VerfasserIn]
• Verfasst von: Limonciel, Alice [VerfasserIn]
• Verfasst von: Long, Anthony [VerfasserIn]
• Verfasst von: Maclennan, Richard [VerfasserIn]
• Verfasst von: Mombelli, Enrico [VerfasserIn]
• Verfasst von: Norinder, Ulf [VerfasserIn]
• Verfasst von: Jain, Sankalp [VerfasserIn]
• Verfasst von: Capinha, Liliana Santos [VerfasserIn]
• Verfasst von: Taboureau, Olivier T. [VerfasserIn]
• Verfasst von: Tolosa, Laia [VerfasserIn]
• Verfasst von: Vrijenhoek, Nanette G. [VerfasserIn]
• Verfasst von: van Vugt-Lussenburg, Barbara M. A. [VerfasserIn]
• Verfasst von: Walker, Paul [VerfasserIn]
• Verfasst von: van de Water, Bob [VerfasserIn]
• Verfasst von: Wehr, Matthias [VerfasserIn]
• Verfasst von: White, Andrew [VerfasserIn]
• Verfasst von: Zdrazil, Barbara [VerfasserIn]
• Verfasst von: Fisher, Ciarán [VerfasserIn]
• Titel: Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action
• Verf.angabe: Sylvia E. Escher, Alejandro Aguayo-Orozco, Emilio Benfenati, Annette Bitsch, Thomas Braunbeck, Katharina Brotzmann, Frederic Bois, Bart van der Burg, Jose Castel, Thomas Exner, Domenico Gadaleta, Iain Gardner, Daria Goldmann, Oliver Hatley, Nazanin Golbamaki, Rabea Graepel, Paul Jennings, Alice Limonciel, Anthony Long, Richard Maclennan, Enrico Mombelli, Ulf Norinder, Sankalp Jain, Liliana Santos Capinha, Olivier T. Taboureau, Laia Tolosa, Nanette G. Vrijenhoek, Barbara M. A. van Vugt-Lussenburg, Paul Walker, Bob van de Water, Matthias Wehr, Andrew White, Barbara Zdrazil, Ciarán Fisher
• E-Jahr: 2022
• Jahr: 29 October 2021
• Umfang: 16 S.
• Fussnoten: Gesehen am 14.02.2022
• Titel Quelle: Enthalten in: Toxicology in vitro
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1987
• Jahr Quelle: 2022
• Band/Heft Quelle: 79(2022) vom: März, Artikel-ID 105269, Seite 1-16
• ISSN Quelle: 1879-3177
• DOI: doi:10.1016/j.tiv.2021.105269
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1789553008

Abstract

Read-across approaches often remain inconclusive as they do not provide sufficient evidence on a common mode of action across the category members. This read-across case study on thirteen, structurally similar, branched aliphatic carboxylic acids investigates the concept of using human-based new approach methods, such as in vitro and in silico models, to demonstrate biological similarity. Five out of the thirteen analogues have preclinical in vivo studies. Three out of them induced lipid accumulation or hypertrophy in preclinical studies with repeated exposure, which leads to the read-across hypothesis that the analogues can potentially induce hepatic steatosis. To confirm the selection of analogues, the expression patterns of the induced differentially expressed genes (DEGs) were analysed in a human liver model. With increasing dose, the expression pattern within the tested analogues got more similar, which serves as a first indication of a common mode of action and suggests differences in the potency of the analogues. Hepatic steatosis is a well-known adverse outcome, for which over 55 adverse outcome pathways have been identified. The resulting adverse outcome pathway (AOP) network, comprised a total 43 MIEs/KEs and enabled the design of an in vitro testing battery. From the AOP network, ten MIEs, early and late KEs were tested to systematically investigate a common mode of action among the grouped compounds. The targeted testing of AOP specific MIE/KEs shows that biological activity in the category decreases with side chain length. A similar trend was evident in measuring liver alterations in zebra fish embryos. However, activation of single MIEs or early KEs at in vivo relevant doses did not necessarily progress to the late KE “lipid accumulation”. KEs not related to the read-across hypothesis, testing for example general mitochondrial stress responses in liver cells, showed no trend or biological similarity. Testing scope is a key issue in the design of in vitro test batteries. The Dempster-Shafer decision theory predicted those analogues with in vivo reference data correctly using one human liver model or the CALUX reporter assays. The case study shows that the read-across hypothesis is the key element to designing the testing strategy. In the case of a good mechanistic understanding, an AOP facilitates the selection of reliable human in vitro models to demonstrate a common mode of action. Testing DEGs, MIEs and early KEs served to show biological similarity, whereas the late KEs become important for confirmation, as progression from MIEs to AO is not always guaranteed.